DealMatrix

🔥Our Deal of the Month May/26 is Isomorphic Labs

Isomorphic Labs, an AI-native drug discovery and development company, has announced a $2.1 billion Series B funding round aimed at accelerating the transition from breakthrough AI research to large-scale real-world drug development applications.

The round was led by Thrive Capital, with participation from existing investors Alphabet Inc. and GV (Google Ventures), alongside new backers including MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, further strengthening the company’s international investor base.

👏 𝘊𝘰𝘯𝘨𝘳𝘢𝘵𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴 𝘵𝘰 𝘵𝘩𝘦 𝘦𝘯𝘵𝘪𝘳𝘦 𝘵𝘦𝘢𝘮!

Isomorphic Labs operates at the intersection of biotechnology, artificial intelligence, and pharmaceuticals, with a focus on accelerating drug discovery through advanced AI models and computational life sciences research. Given the company’s current Series B stage, European benchmarks (Q1 2026) for AI-enabled biotechnology and pharmaceutical businesses indicate ⤵️

Valuation ranges of EV/Sales multiples of 3.61x - 4.99x, and EV/EBITDA multiples of 16.84x - 20.68x.

➡️ Further information on valuation multiples in these sectors is available through the DealMatrix Platform – Multiples Database at https://platform.dealmatrix.com

🔥 𝗗𝗲𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗪𝗲𝗲𝗸 🔥 #18: Former Google DeepMind researcher’s AI startup raises record $1.1 billion seed funding to pursue superintelligence

Ineffable Intelligence is targeting superintelligence and was founded in late 2025 by UCL professor and former head of DeepMind’s reinforcement learning team, David Silver. According to the company, its seed round is the largest ever raised in Europe, valuing the business at $5.1 billion.

The round was co-led by U.S. venture firms Sequoia Capital and Lightspeed, with additional backing from NVIDIA, DST Global, Index Ventures, Google, and the U.K.’s Sovereign AI Fund, among others.

👏 𝘊𝘰𝘯𝘨𝘳𝘢𝘵𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴 𝘵𝘰 𝘵𝘩𝘦 𝘦𝘯𝘵𝘪𝘳𝘦 𝘵𝘦𝘢𝘮!

Ineffable Intelligence operates in the field of artificial intelligence, with a focus on developing machine learning systems that improve through interaction and experiential learning. Given the company’s current stage, European benchmarks (Q1 2026) for AI and machine learning businesses indicate valuation ranges of EV/Sales multiples of 3.76x - 4.14x, and EV/EBITDA multiples of 16.84x - 18.96x.

➡️ Further information on valuation multiples in these sectors is available through the DealMatrix Platform: https://platform.dealmatrix.com

🔥 𝗗𝗲𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗪𝗲𝗲𝗸 🔥 #14: 9fin raises $170M Series C at $1.3B valuation to scale AI platform for debt markets

The financing was led by HarbourVest Partners, with Canada Pension Plan Investment Board joining alongside existing backers redalpine, Highland Europe, Spark Capital, and Seedcamp.

👏 𝘊𝘰𝘯𝘨𝘳𝘢𝘵𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴 𝘵𝘰 𝘵𝘩𝘦 𝘦𝘯𝘵𝘪𝘳𝘦 𝘵𝘦𝘢𝘮!

9fin operates at the intersection of artificial intelligence and financial market intelligence, providing an AI-powered platform that transforms debt market data into actionable insights for credit professionals.

Consistent with this positioning and the company’s Series C-stage financing, relevant European sector benchmarks as of Q4 2025 for Fintech and applied AI platforms indicate valuation ranges of EV/Sales 3.55x - 5.24x and EV/EBITDA 16.83x - 20.21x.

➡️ Further information on valuation multiples in these sectors is available through the DealMatrix Platform: https://platform.dealmatrix.com/